| DrugRepV_0388 | Hexachlorophene | Dermatologicals | Bacterial infections | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0403 | Podofilox | Dermatologicals | External genital warts | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0776 | Methoxsalen | Dermatologicals | Psoriasis | Vitiligo | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (94.295 %) | Approved | 27476412 |
| DrugRepV_0790 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (71.825 %) | Approved, Investigational | 27476412 |
| DrugRepV_0799 | Hexachlorophene | Dermatologicals | Bacterial infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (73.95 %) | Approved, Withdrawn | 27476412 |
| DrugRepV_0811 | Podofilox | Dermatologicals | External genital warts | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (63.735 %) | Approved | 27476412 |
| DrugRepV_0817 | Tazarotene | Dermatologicals | Psoriasis, acne and sun damaged skin | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (60.1 %) | Approved | 27476412 |
| DrugRepV_0821 | Econazole Nitrate | Dermatologicals | Fungal infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (69.6 %) | Approved | 27476412 |
| DrugRepV_0823 | Calcipotriene | Dermatologicals | Psoriasis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (61.795 %) | Approved | 27476412 |
| DrugRepV_0832 | Ciclopirox | Dermatologicals | Fungal infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (65.575 %) | Approved | 27476412 |
| DrugRepV_0845 | Alitretinoin | Dermatologicals | Cutaneous lesions in patients with AIDS-related Kaposi sarcoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (61.94 %) | Approved | 27476412 |
| DrugRepV_0867 | Mequinol | Dermatologicals | Solar lentigines | Hyperpigmented lesions | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.96 %) | Approved | 27476412 |
| DrugRepV_0914 | Imiquimod | Dermatologicals | Genital and perianal warts/condyloma acuminata | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.785 %) | Approved, Investigational | 27476412 |
| DrugRepV_0920 | Acitretin | Dermatologicals | Psoriasis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (58.15 %) | Approved | 27476412 |
| DrugRepV_0958 | Halcinonide | Dermatologicals | Dermatoses | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.67 %) | Approved, Investigational, Withdrawn | 27476412 |
| DrugRepV_0993 | Clotrimazole | Dermatologicals | Fungal infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.76 %) | Approved | 27476412 |
| DrugRepV_1048 | Azelaic acid | Dermatologicals | Acne vulgaris | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.95 %) | Approved | 27476412 |
| DrugRepV_1083 | Eflornithine Hydrochloride | Dermatologicals | Facial hirsutism | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.285 %) | Approved, Withdrawn | 27476412 |
| DrugRepV_1119 | Butenafine Hydrochloride | Dermatologicals | Fungal infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.54 %) | Approved | 27476412 |
| DrugRepV_1124 | Mafenide Hydrochloride | Dermatologicals | Severe burns | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.525 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1135 | Fluocinonide | Dermatologicals | Eczema | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.945 %) | Approved, Investigational | 27476412 |
| DrugRepV_1162 | Flurandrenolide | Dermatologicals | Skin disorder | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.98 %) | Approved | 27476412 |
| DrugRepV_1171 | Naftifine Hydrochloride | Dermatologicals | Fungal infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.795 %) | Approved | 27476412 |
| DrugRepV_1173 | Oxiconazole Nitrate | Dermatologicals | Dermal fungal infection | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.345 %) | Approved | 27476412 |
| DrugRepV_1220 | Amcinonide | Dermatologicals | Inflammatory and pruritic | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.13 %) | Approved | 27476412 |
| DrugRepV_1228 | Sulfacetamide Sodium | Dermatologicals | Bacterial infections (Vaginitis, keratitis, acute conjunctivitis, and blepharitis) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.36 %) | Approved | 27476412 |
| DrugRepV_1251 | Isotretinoin | Dermatologicals | Acne | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.065 %) | Approved | 27476412 |
| DrugRepV_1252 | Griseofulvin | Dermatologicals | Fungal infections (Ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.7 %) | Approved, Investigational, Vet approved | 27476412 |
| DrugRepV_1260 | Silver Sulfadiazine | Dermatologicals | Wound sepsis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.965 %) | Approved | 27476412 |
| DrugRepV_1354 | Desoximetasone | Dermatologicals | Dermatoses, skin allergies and psoriasis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.515 %) | Approved | 27476412 |
| DrugRepV_1377 | Halobetasol Propionate | Dermatologicals | Dermatoses | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.565 %) | Approved | 27476412 |
| DrugRepV_1393 | Sulconazole Nitrate | Dermatologicals | Fungal infections (Tinea cruris and Tinea corporis) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.21 %) | Approved | 27476412 |
| DrugRepV_1408 | Clobetasol Propionate | Dermatologicals | Psoriasis and dermatosis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.13 %) | Approved | 27476412 |
| DrugRepV_1472 | Terbinafine Hydrochloride | Dermatologicals | Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.665 %) | Approved, Investigational, Vet approved | 27476412 |
| DrugRepV_1490 | Desonide | Dermatologicals | Inflammatory disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (37.765 %) | Approved | 27476412 |
| DrugRepV_1515 | Adapalene | Dermatologicals | Acne vulgaris | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (34.305 %) | Approved | 27476412 |
| DrugRepV_1577 | Clotrimazole | Dermatologicals | Fungal infections | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (33 %) | Approved | 26217313 |
| DrugRepV_1929 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Zika virus | H/PF/2013 | NA | Plaque assay | Decrease (2 Logs) | Approved, Investigational | 28814523 |
| DrugRepV_1934 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Zika virus | H/PF/2013 | NA | Real-time PCR | Decrease (0.2 %) | Approved, Investigational | 28814523 |
| DrugRepV_1939 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Zika virus | H/PF/2013 | NA | Immunoflourescence assay | Decrease | Approved, Investigational | 28814523 |
| DrugRepV_2212 | Butenafine Hydrochloride | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.76085859 %) | Approved | 27742486 |
| DrugRepV_2223 | Methoxsalen | Dermatologicals | Psoriasis | Vitiligo | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.14420741 %) | Approved | 27742486 |
| DrugRepV_2237 | Terbinafine Hydrochloride | Dermatologicals | Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.51264741 %) | Approved, Investigational, Vet approved | 27742486 |
| DrugRepV_2271 | Isotretinoin | Dermatologicals | Acne | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.00736344 %) | Approved | 27742486 |
| DrugRepV_2273 | Clobetasol Propionate | Dermatologicals | Psoriasis and dermatosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.9664796 %) | Approved | 27742486 |
| DrugRepV_2277 | Econazole Nitrate | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.89847179 %) | Approved | 27742486 |
| DrugRepV_2348 | Ciclopirox | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.26315249 %) | Approved | 27742486 |
| DrugRepV_2372 | Adapalene | Dermatologicals | Acne vulgaris | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.66633546 %) | Approved | 27742486 |
| DrugRepV_2422 | Imiquimod | Dermatologicals | Genital and perianal warts/condyloma acuminata | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.85929889 %) | Approved, Investigational | 27742486 |
| DrugRepV_2451 | Bifonazole | Dermatologicals | Fungal infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.03205443 %) | Approved | 27742486 |
| DrugRepV_2512 | Tetracaine Hydrochloride | Dermatologicals | Local dermal analgesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.0174276 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2523 | Nadifloxacin | Dermatologicals | Acne Vulgaris | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.3986672 %) | Investigational | 27742486 |
| DrugRepV_2562 | Docosanol | Dermatologicals | Herpes simplex episodes | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.0813812 %) | Approved | 27742486 |
| DrugRepV_2662 | Fluocinonide | Dermatologicals | Eczema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3646739 %) | Approved, Investigational | 27742486 |
| DrugRepV_2676 | Naftifine Hydrochloride | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5283589 %) | Approved | 27742486 |
| DrugRepV_2705 | Tioxolone | Dermatologicals | Seborrhea or Seborrheic dermatitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0190059 %) | Experimental | 27742486 |
| DrugRepV_2793 | Tazarotene | Dermatologicals | Psoriasis, acne and sun damaged skin | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7953339 %) | Approved | 27742486 |
| DrugRepV_2800 | Octocrylene | Dermatologicals | Sunburn | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.009058 %) | Approved | 27742486 |
| DrugRepV_2810 | Amorolfine Hydrochloride | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.3091551 %) | Approved | 27742486 |
| DrugRepV_2817 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.4573493 %) | Approved, Investigational | 27742486 |
| DrugRepV_2859 | Ciclopirox ethanolamine | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.0876735 %) | Approved | 27742486 |
| DrugRepV_2860 | Clotrimazole | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.1110368 %) | Approved | 27742486 |
| DrugRepV_2873 | Acitretin | Dermatologicals | Psoriasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.7772745 %) | Approved | 27742486 |
| DrugRepV_2882 | Tolnaftate | Dermatologicals | Skin infections (Fungal) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.2646691 %) | Approved | 27742486 |
| DrugRepV_2883 | Desonide | Dermatologicals | Inflammatory disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.3310624 %) | Approved | 27742486 |
| DrugRepV_2917 | Terbinafine | Dermatologicals | Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.718001 %) | Approved, Investigational, Vet approved | 27742486 |
| DrugRepV_2920 | Fenticonazole nitrate | Dermatologicals | Fungal infections (Vulvovaginal candidiasis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.000576 %) | Experimental | 27742486 |
| DrugRepV_2935 | Monobenzone | Dermatologicals | Vitiligo | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-16.860885 %) | Approved | 27742486 |
| DrugRepV_3055 | Clotrimazole | Dermatologicals | Fungal infection | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (30 %) | Approved | 26752081 |
| DrugRepV_3056 | Bifonazole | Dermatologicals | Fungal infection | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (22 %) | Approved | 26752081 |
| DrugRepV_4078 | Clotrimazole | Dermatologicals | Fungal infections | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4086 | Clotrimazole | Dermatologicals | Fungal infections | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4215 | Ingenol | Dermatologicals | NA | Chikungunya virus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 25970561 |
| DrugRepV_4216 | Ingenol-3-mebutate | Dermatologicals | Actinic keratosis | Chikungunya virus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 25970561 |
| DrugRepV_4217 | Ingenol-3,20-dibenzoate | Dermatologicals | NA | Chikungunya virus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 25970561 |
| DrugRepV_5751 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Dengue virus | DENV-2 replicon |  | Luciferase reporter assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_5772 | Cetrimonium Bromide | Dermatologicals | Sepsis | Dengue virus | Singapore isolates | | Plaque assay | Decrease (90 %) | Approved | 25251726 |
| DrugRepV_5783 | Dioxybenzone | Dermatologicals | Sunburn | Dengue virus | Singapore isolates | | Plaque assay | Decrease (65 %) | Approved | 25251726 |
| DrugRepV_5807 | C6 Ceramide | Dermatologicals | Skin disorder | Dengue virus | NA | | Immunoflourescence assay | Decrease (84.06 %) | Approved | 22155902 |
| DrugRepV_5819 | Cantharidin | Dermatologicals | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (51.87 %) | Approved | 22155902 |
| DrugRepV_5830 | Trimethylpsoralen,4,5,8- | Dermatologicals | NA | Dengue virus | NA | | Immunoflourescence assay | Decrease (41.86 %) | NA | 22155902 |
| DrugRepV_6035 | Azelaic acid | Dermatologicals | Acne vulgaris | Dengue virus | 16681 | | Focus forming assay | Decrease (36.6 %) | Approved | 30055216 |
| DrugRepV_6320 | C6 Ceramide | Dermatologicals | Skin disorder | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (84.06 %) | Approved | 22155902 |
| DrugRepV_6332 | Cantharidin | Dermatologicals | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (51.87 %) | Approved | 22155902 |
| DrugRepV_6343 | Trimethylpsoralen, 4,5,8- | Dermatologicals | NA | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (41.86 %) | NA | 22155902 |
| DrugRepV_6922 | Ingenol | Dermatologicals | NA | Human immunodeficiency virus | IIIB | | MTT assay | Decrease (50 %) | NA | 25970561 |
| DrugRepV_6923 | Ingenol-3-mebutate | Dermatologicals | Actinic keratosis | Human immunodeficiency virus | IIIB | | MTT assay | Decrease (50 %) | Approved | 25970561 |
| DrugRepV_6924 | Ingenol-3,20-dibenzoate | Dermatologicals | NA | Human immunodeficiency virus | IIIB | | MTT assay | Decrease (50 %) | NA | 25970561 |
| DrugRepV_6952 | Ingenol | Dermatologicals | NA | Human immunodeficiency virus | ROD | | MTT assay | Decrease (50 %) | NA | 25970561 |
| DrugRepV_6953 | Ingenol-3-mebutate | Dermatologicals | Actinic keratosis | Human immunodeficiency virus | ROD | | MTT assay | Decrease (50 %) | Approved | 25970561 |
| DrugRepV_6954 | Ingenol-3,20-dibenzoate | Dermatologicals | NA | Human immunodeficiency virus | ROD | | MTT assay | Decrease (50 %) | NA | 25970561 |
| DrugRepV_7010 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28814523 |
| DrugRepV_7014 | Sulconazole Nitrate | Dermatologicals | Fungal infections (Tinea cruris and Tinea corporis) | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | NA | 28814523 |
| DrugRepV_7019 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Plaque assay | Decrease (5 Logs) | Approved, Investigational | 28814523 |
| DrugRepV_7024 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Real-time PCR | Decrease (0.01 %) | Approved, Investigational | 28814523 |
| DrugRepV_7029 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Immunoflourescence assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_7034 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (100 %) | Approved, Investigational | 28814523 |
| DrugRepV_7039 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (95 %) | Approved, Investigational | 28814523 |
| DrugRepV_7044 | Pimecrolimus | Dermatologicals | Atopic dermatitis | West Nile virus | WNV replicon | | Luciferase reporter assay | Decrease (88 %) | Approved, Investigational | 28814523 |
| DrugRepV_7598 | Promethazine | Dermatologicals | Rhinitis, allergic conjunctivitis, allergic reactions, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness. | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52292 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7599 | Promethazine | Dermatologicals | Rhinitis, allergic conjunctivitis, allergic reactions, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness. | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52292 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_8140 | Ciclopirox ethanolamine | Dermatologicals | Fungal infections | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8141 | Econazole Nitrate | Dermatologicals | Fungal infections | Vaccinia virus | NA | | NA | Decrease (55.1 %) | Approved | 32708182 |
| DrugRepV_8241 | Bergapten | Dermatologicals | Severe Generalized Atopic Dermatitis | Vaccinia virus | NA | | NA | Decrease (7.6 %) | Investigational | 32708182 |